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Abstract 
Background: Deceased organ donors are routinely screened for behaviors that 
increase the risk of transmissible blood borne viral (BBV) infection, but the impact of 
this information on organ donation and transplant outcome is not well documented. 
Our aim was to establish the impact of such behavior on organ donation and 
utilization, as well transplant recipient outcomes. 
Methods: We identified all UK deceased organ donors from 2003-2015 with a 
disclosed history of increased risk behavior (IRB) including intravenous drug use 
(IVDU), imprisonment and increased risk sexual behavior.  
Results: Of 17 262 potential donors, 659 (3.8%) had IRB for BBV and 285 (1.7%) 
were seropositive for BBV, of whom half had a history of IRB (mostly IVDU 
(78.5%)). Of actual donors with IRB, 393 were seronegative for viral markers at time 
of donation. A history of recent IVDU was associated with fewer potential donors 
proceeding to become actual organ donors (64% vs. 75%, p=0.007). Donors with IRB 
provided 1091 organs for transplantation (624 kidneys and 467 other organs). 
Transplant outcome was similar in recipients of organs from donors with and without 
IRB. There were 3 cases of unexpected HCV transmission, all from an active IVDU 
donor who was HCV seronegative at time of donation, but was found to be viraemic 
on retrospective testing 
Conclusion: Donors with a history of IRB provide a valuable source of organs for 
transplantation with good transplant outcomes and there is scope for increasing the 
use of organs from such donors. 
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Introduction 
Unintended transmission of Hepatitis C (HCV), Hepatitis B (HBV), Human 
Immunodeficiency Virus (HIV) and Human T lymphotrophic virus (HTLV) from 
deceased organ donors is a rare but serious complication of organ transplantation (1). 
This risk is minimized by performing relevant laboratory screening investigations in 
deceased donors prior to implantation of their organs. Currently available screening 
strategies cannot completely discount the presence of a recently acquired viral 
infection, and considerable importance is attached to the identification of donors with 
a history of increased risk behavior (IRB) associated with the acquisition of HCV, 
HIV, HBV and HTLV(1-4). While the discard of organs from those with a history of 
IRB would minimize disease transmission, it would markedly reduce the number of 
transplants performed. Consequently, the risk of disease transmission from donors 
with IRB needs to be balanced against the potential benefits of organ transplantation. 
 
Solid organ donors who have a history of prior or current intravenous drug use 
(IVDU), or of recent or historical imprisonment, and those who have a history of 
high-risk sexual behavior are viewed at greatest risk of transmission of BBV (2,3). In 
the United Kingdom (UK), current guidance from the Advisory Committee for the 
Safety of Blood, Tissues and Organs and the European Directive on Organ Donation 
requires that detailed information on „behavioral history that could have put the donor 
at an increased risk of blood borne viruses‟ be obtained (5). The information needed 
includes „questions about risk behaviors such as recreational drug use, men who have 
sex with men (MSM), and risks such as accidental body fluid exposure‟ (5). UK 
guidance on donor assessment is consistent with that in the United States where the 
need to assess behavioral risk factors for a donor to be at increased risk of 
transmitting HIV, HBV and HCV is highlighted (2). The donor history with respect to 
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such IRB also provides an important context for the interpretation of the results from 
microbiological screening for HIV, HCV, HBV and HTLV (3,5,6). Current screening 
tests for viral markers have limited sensitivity, and serological screening may result in 
an infective window period of up to 70 days following infection when antibodies to 
virus are undetectable (6). 
 
We report the UK experience of deceased organ donors, both potential and 
actual, with a history of IRB, highlighting the overall prevalence and types of IRB. 
Our aim was to establish the impact of IRB on organ donation and utilization, as well 
as on their transplant recipient outcomes. 
 
Methods 
Identification of deceased organs donors with increased risk behavior 
The UK Transplant Registry was examined to identify all deceased organ 
donors between 1
st
 January 2003 and 31
st
 December 2015, who had a history of any 1 
of the following IRB: IVDU, current or previous imprisonment, MSM, sex in 
exchange for money or drugs, and high risk sexual partner (defined as a sexual 
relationship with any of the previously mentioned increased risk groups). For the 
purposes of this study, “potential donors” were defined as deceased donors for whom 
consent/ authorization for organ donation had been obtained, “actual organ donors” as 
deceased donors who had 1 or more solid organs removed for transplantation on the 
basis that recipient centers had provisionally agreed to use them for transplantation, 
and “utilized organ donors” as actual organ donors whose organs where eventually 
transplanted. The decision as to whether or not a potential donor proceeds to organ 
donation is dependent on transplant clinicians at individual transplant centers 
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indicating that they are willing to accept the organs for transplantation. There are no 
centralized clinical advisors involved in this decision.  
In the UK, a donor transplant coordinator (designated in 2008 as a Specialist 
Nurse in Organ Donation) is required to enquire from the next of kin, medical notes 
and the potential donor‟s family doctor, whether there is a history of IRB and record 
these findings. Additional UK guidance published in 2000 highlighted the 
requirement to screen potential organ donors for behavior associated with BBV.  
 
Free text entries of all potential donors were searched using the terms 
„intravenous drug use‟ „sex worker‟ „Men who have sex with men‟ and „prison‟. All 
common abbreviations, misspellings, synonymous terms and colloquialisms of the 
above search terms were also searched. Donors with a history of IVDU and 
imprisonment were sub-categorized based on whether or not they had been an IVDU 
or imprisoned during the preceding 12 months. Donors with a history of high-risk 
sexual behavior were sub-categorized according to the type behavior into any 1 of 
„high risk partner‟, „sex worker‟, and „prior high risk partner‟.  
 
It is important to note that a number of patients did not fall into the category of 
potential donors because formal consent for donation was not sought for a variety of 
reasons that included a belief by the clinicians caring for the patient that the patient‟s 
IRB would exclude organ and tissue donation. Information on the number of patients 
that did not progress to become potential donors for the entire study period (2003-
2015) was not available but the potential donor audit (a prospective registry of all 
patients aged <80 years who died in critical care units of acute UK hospitals, 
irrespective of their medical suitability to become organ donors) was interrogated to 
obtain information on patients excluded from the present analysis. Between January 
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2009 and 31
st
 December 2015 there were 12 040 potential donors analyzed in the 
present study, and during the same period the Potential Donor Audit showed that 
1022 patients with an identified IRB (89% IVDU) did not get consented for organ 
donation for a variety of reasons that included IRB. In 86 patients excluded from the 
present study, IVDU was stated explicitly as a reason why the patient‟s family was 
not approached for consent for organ donation.  
 
Identification of recipients of organs from donors with increased risk behavior 
The UK transplant registry was examined to identify recipients of organs from 
donors with IRB and information on outcome (patient and graft survival) obtained. 
UK transplant centers are required to notify NHSBT of any potential donor-derived 
disease transmission and adverse events relating to the donation process. This 
reporting requirement became mandatory when the new European Union Organ 
Donation Directive guidelines came into effect (2010) and was written into UK law in 
the Quality and Safety of Organs for Transplantation Regulations (2012).  Prior to 
2010, recipient centers were expected, according to UK guidance, to report any 
adverse outcomes in recipients relating directly to the organ donation process to 
NHSBT. Details of any donor transmitted infections were collected from a designated 
transplant incident reporting registry held by NHSBT.  
 
Statistical Analysis 
Univariate analysis comparing clinical characteristics between IRB and non-IRB 
potential donors, who were seronegative for BBV, was carried out using Student‟s t 
test for approximately normal continuous data, and the Mann-Whitney U test for 
abnormal continuous data. Categorical comparisons were made using the χ2–squared 
test.  
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Kaplan-Meier curves were used to show death-censored graft survival and 
patient survival and the univariate log-rank test was used to compare unadjusted 
survival rates.  
Cox proportional hazards regression model and a logistic regression model 
were fitted in a stepwise selection method in order to control for potentially 
confounding factors. Donor related variables considered for inclusion in the 
multivariate model were donor age, donor type, ethnic group, sex, past medical 
history of diabetes and hypertension, liver disease, cardiac disease, smoking history 
and whether the donor had a history of IRB. Recipient factors included were age, 
ethnicity, sex, primary renal disease, Human Leukocyte Antigen (HLA) mismatch 
level and cold ischemic time.  
 
All analyses were performed using Statistical Analysis System (SAS) (version 
9.3) and p values less than 0.05 were deemed to be statistically significant (7).  
HLA mismatch level (levels 1-4) was defined according to UK allocation 
policy for kidneys from brain-death donors and was based on the mismatch between 
donor and recipient (8). 
 
The United Kingdom Model for End-Stage Liver Disease score was used 
when assessing differences in liver recipient characteristics. This score is calculated 
based on the patient‟s international normalized ratio, serum creatinine, serum 
bilirubin, and serum sodium (9,10).  
 
Results 
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 One or more IRB was identified in 659 (3.8%) of potential deceased donors, 
and 454 (3.6%) of actual organ donors. Of the potential donors with a history of IRB, 
47% had a history of IVDU, 33% a history of imprisonment, 10% were MSM, and 
9.9% a history of high risk sexual behavior. For actual donors with a history of IRB, 
41% had a history of IVDU, 37% had a history of imprisonment, and 21% had a 
history of high risk sexual behavior, and these proportions did not differ significantly 
from the behaviors in potential donors (p=0.147).  
 
Organ donors who were seropositive for HIV, HCV, HBV and HTLV  
Overall, 285 (1.7%) of potential organ donors were found to be seropositive 
for BBVs markers. 104 (36.5%) seropositive potential donors proceeded to organ 
donation; in contrast to the 78% conversion rate observed in seronegative potential 
donors (p<0.001). Organs from 81 (77.8%) of the seropositive organ donors were 
subsequently transplanted, compared to 95.7% of seronegative organ donors 
(p<0.001).  
 
Half (50.5%) of potential donors who were seropositive for viral infection had 
a history of IRB, and in most (78.5%) this included IVDU. A history of 
imprisonment, MSM and high risk sexual behavior was less common (16.7%, 2.7% 
and 2.1% respectively). The clinical characteristics of potential and actual 
seropositive donors are shown in table 1. Positive serology for HCV was more 
common in donors with a history of IRB. In contrast, markers of HIV, HBV and 
HTLV were all more common in seropositive donors with no history of IRB (table 1).  
 
The types of organs from seropositive organ donors that were used for 
transplantation differed according to whether or not there was a history of IRB. The 
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62 organ donors with a history of IRB provided 48 livers and 11 kidneys that were 
used for transplantation, whereas the 42 donors with no history of IRB donated 25 
livers and 32 kidneys that were transplanted (p<0.001). 
 
 
Increased risk behavior and organ donation in donors who were seronegative for 
viral infection 
To examine the association between IRB and organ donation, all seropositive 
potential donors were excluded from subsequent analysis. After exclusion, there were 
16 977 remaining potential donors of which 12 737 (75%) proceeded to organ 
donation (figure 1). A history of IRB was identified in 515 (3%) of potential and 392 
(3%) of actual organ donors, suggesting that overall, a history of IRB did not 
adversely influence the decision to proceed to organ donation. 25% of potential 
donors with no history of IRB and 24% of those with a history of IRB did not proceed 
to donation (p=NS). Potential donors with a history of IRB were, when compared to 
those with no history of IRB, much younger, and significantly less likely to have 
hypertension, cardiac disease and diabetes (table 2). Potential donors with IRB were, 
however, more likely to be smokers and to have a history of alcohol abuse. 
 
There were significant differences in the conversion rate from potential to 
actual donors according to the type of IRB (figure 2). Potential donors with a history 
of IVDU were less likely to proceed to organ donation than donors with no history of 
IRB and this effect was most marked in potential donors with a history of recent 
rather than historical IVDU Those with a history high risk sexual behavior alone were 
as likely to proceed to donation as those with no history of high risk sexual behavior 
(figure 2). History of imprisonment (previous or current) alone was associated with an 
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increased rate of proceeding to donation compared to donors with no history of IRB 
(figure 2).  However, when a logistic regression model was fitted to adjust for the 
significant differences in age and co-morbidity between donors with or without a 
history of IRB, IRB was associated with significantly fewer potential organ donors 
becoming actual organ donors (odds ratio=1.580 (95% CI 1.273-
1.962,p<0.001).When the logistic regression model was fitted for the different types 
of IRB, IVDU (both recent and historical) was associated with significantly fewer 
potential organ donors becoming actual organ donors (odds ratio=3.552 (95% CI 
(2.373-5.315), p<0.001 and odds ratio =1.984 (95% CI 1.205-3.268) p=0.007, 
respectively )(table 3). 
 The number of potential donors with a history of IRB increased markedly over 
the 13-year study period and the percentage of donors proceeding to donation also 
rose in the latter part of the study period (figure 3).   
 
Clinical characteristics of actual organ donors with history increased risk behaviors 
 Potential donors with a history of IRB, that proceeded to become actual organ 
donors were younger (39.8 ± 12.6 years vs. 44.3 ± 11.6 years, p<0.001) and more 
likely to be DBD than DCD donors (36.2% DCD vs. 82.9% DCD, p<0.001) than 
those potential donors with IRB who did not proceed to organ donation. 
 
The clinical characteristics of the 392 actual organ donors with a history of 
IRB, along with the clinical characteristics of all other deceased organ donors are 
shown in table 3. Actual organ donors with a history of IRB were younger, more often 
males and more likely to be of an ethnic minority other than white. Organ donors with 
a history of IRB were more likely to have a history of smoking and of alcohol abuse 
(table 4). 
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Clinical characteristics of recipients receiving organs from donors with increased 
risk behavior 
Over the 13-year study period, a total 1091 transplants were carried out using 
organs from seronegative deceased donors with a history of IRB (624 kidney, 278 
liver, 63 heart, 39 lung (including 1 lung pair), 2 heart and lung transplants, 84 
pancreases, and 1 bowel transplant).  
Recipients of kidneys from donors with a history of IRB were younger, more 
often of nonwhite ethnicity and less well matched for HLA than recipients of kidneys 
from donors with no IRB (table 5). Recipients of kidneys from donors with IRB spent 
a similar amount of time on the transplant waiting list and had a similar duration of 
dialysis pretransplant when compared to those who received kidneys from donors 
without IRB. Recipients of kidneys from donors with IRB had similar graft and 
patient survival to those who received kidneys from all other deceased donors (figure 
4a). When the recipients of the different types of IRB were compared to all other 
recipients, a donor history of recent IVDU did not adversely influence patient or graft 
survival (figure 4b). 
 
Recipients of livers from donors with a history of IRB were older, more often 
male, had a lower UKELD score, and more often HCV positive than recipients of 
livers from donors with no IRB (Table 6). Similarly, patient and graft survival 
following liver transplantation was comparable for recipients of livers from donors 
with and without IRB (figure 5a and figure 5b).  
 
Because of the differences in donor and recipient demographics between 
recipients that received organs from donors with a history of IRB compared to those 
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that did not, a Cox proportional hazards regression model was fitted to adjust for 
donor and recipient age, donor history of hypertension, HLA mismatch, cold ischemic 
time and primary recipient disease. This showed that patient survival after kidney 
transplantation was not adversely affected by a donor history of IRB (Table S1, SDC, 
http://links.lww.com/TP/B422). After assessing whether the different sub-types of 
IRB adversely impacted on transplant outcome the multivariate analysis indicated 
recipients of kidneys from donors with high-risk sexual behavior had significantly 
worse patient survival than those who received kidneys from donors with no history 
of high-risk sexual behavior, even after adjusting for donor and recipient factors. Each 
of the high-risk sexual behaviors was assessed in turn, and this revealed that it was 
only those who received kidneys from donors with a high-risk sexual partner that had 
worse patient survival. 
 
Disease transmission 
From the 1091 organ transplants from donors with IRB, 1 liver recipient and 2 
renal recipients (all from the same organ donor) developed donor-derived HCV 
infection.  The donor of the organs had a history of recent IVDU, and tested negative 
for HCV antibody at time of donation. Retrospective testing of the donor serum 
obtained at donation was positive for HCV Ribonucleic Acid. The liver recipient was 
known to be HCV positive at time of transplantation, but it was noted that the 
predominant HCV genotype changed from genotype 1 pretransplant to donor 
genotype 3 after transplant. The 2 renal recipients were both HCV negative prior to 
transplantation. 
 
There were no reported unexpected HIV, HBV or HTLV transmissions from 
these IRB donors. 
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Discussion 
Routine screening of all potential organ donors for a history of IRB to 
determine risk of transmission of BBV infection is routinely undertaken in most 
countries to help inform the decision on organ usage. The present analysis provides 
insight on the impact of this policy on organ donation and utilization in the UK, 
where the prevalence of blood borne viral infection is slightly lower than that in the 
USA and broadly similar to Western Europe (11-14).  
Around 4% of all potential organ donors, for whom consent for donation was 
obtained, had a history of IRB and 22% of these (2% of all potential donors) were 
seropositive for blood borne viral infection (mostly HCV), at the time organ donation 
was being considered and over half had a history of IRB. Positive serology for blood 
borne viruses may indicate a very high risk of disease transmission during 
transplantation, and enables an informed decision on whether to proceed with organ 
donation, and if so, to allocate organs to appropriate potential recipients; in the 
majority of cases the recipients are likely to be selected on the basis that they already 
have infection corresponding to that identified in the donor.  
 
In the present study, we were particularly interested in the extent to which IRB 
in seronegative potential donors impacted on organ donation and transplantation. 
Overall, around 3/4 of all potential organ donors in the UK proceeded to become 
actual organ donors, on the basis that transplant implanting centers had provisionally 
accepted them for transplantation. A history of IRB (all types) was not associated 
with a reduction in the proportion of potential donors that proceeded to become organ 
donors. However, a history of IVDU accounted for nearly half of all IRB and was 
associated with a relatively small but significant reduction in the proportion of 
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potential donors proceeding to donation, especially when the drug use may have been 
recent.   
 
Potential donors with IRB were significantly younger and had less additional 
comorbidity than those with no IRB, and when these variables were taken into 
account by logistic regression analysis, IVDU (both recent and historical) were 
associated with donors not proceeding to become actual organ donors. Our analysis of 
the potential donor audit (a prospective registry of all patients aged <80 years who 
died in critical care units of acute UK hospitals, irrespective of their medical 
suitability to become organ donors) indicated that a large number of these identified 
registry patients did not get consented for organ donation because of their history of 
IRB (in particular IVDU).  
 
The number of potential donors with IRB in the present study increased 
markedly over the 13-year study period. This likely reflects, for the most part, a true 
increase in the number of such donors over time, in line with the general trend 
towards increased consideration of organs from other types of high-risk donor (15). 
However, it is also likely that some of the increase in potential donors with IRB over 
time may be attributable to a bias in data capture, as clinical practice in organ donor 
screening by transplant coordinators and documentation became more standardized.  
 
While the risk of disease transmission in seronegative donors with IRB is very 
low, not all transplant centers routinely assess recipients for graft-derived acquisition 
of blood borne viral disease and consequently the present study may provide and 
underestimate of disease transmission from donors with IRB. Although seronegative 
donors with a history of IRB represent a small proportion of the total donor 
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population they made a significant contribution to organ transplantation in the UK 
over the 13-year study period, providing organs for over a thousand transplants.  
 
There were 3 confirmed transmissions of HCV to 2 renal transplant recipients 
and 1 liver transplant recipient. All 3 episodes of disease transmission originated from 
the same donor, who was known to be an active IVDU at time of donation. Using 
standard serological testing the window period from infection with HCV to detection 
by antibody assays is around 70 days (6,16-18) and with Nucleic Acid Technology 
(NAT) is 3-5 days (6,16,18). However, both serological testing and NAT testing 
carries the risk of false positive results and hence the unnecessary discard of 
potentially infection free organs from potential donors. NAT testing is only currently 
available in selected UK centers and recent evidence suggests that NAT testing would 
improve utilization of organs from IRB donors, but not from donors with no history of 
IRB (6). Hence even when NAT testing is available a thorough history regarding IRB 
is still important to aide interpretation of positive results. 
 
As might be expected, recipients of organs from seronegative donors with IRB 
had transplant outcomes (patient and graft survival) comparable to recipients of 
organs from deceased donors with no history of IRB, even after adjustment for 
differences in donor and recipient demographics. However, those who received 
kidneys from donors with a high-risk sexual partners had worse patient survival than 
all other deceased donors. The exact cause of this remains unclear. When the causes 
of renal recipient death in this cohort were examined, no deaths (n=8) were on 
inspection attributable to disease transmission from the donor (n=1 Gastro-intestinal 
hemorrhage, n=1 hemorrhage from graft site, n=1 septicemia, n=1 liver viral hepatitis, 
n= 2 posttransplant lymphoproliferative disorder, n= 1 nonlymphoid malignant 
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disease, n=1 ischemic heart disease). The case of viral hepatitis was fulminant liver 
failure secondary to HCV genotype 1b, which was already present in the recipient 
prior to transplantation. There was no significant difference in graft or patient survival 
in recipients of livers from donors with high-risk sexual behavior and all other 
deceased donors.  
 
The comparison of recipient characteristics according to whether or not they 
received a kidney from a donor with a history of IRB revealed that recipients of 
kidneys from donors with IRB were significantly younger and significantly more 
likely to be of nonwhite ethnicity. Donors with a history of IRB were also 
significantly younger and of nonwhite ethnicity than all other deceased donors, and 
kidney allocation and acceptance policies in terms of age, blood group and HLA 
matching would likely explain the differences observed in recipient demographics. In 
support, it was notable that for liver transplant recipients, where HLA-matching is not 
undertaken there was no significant difference in the ethnicity of recipients according 
to whether or not they received a liver from a donor with IRB. Because kidney donors 
with IRB were significantly younger than other deceased kidney donors, and 
recipients of kidneys from younger donors have improved transplant outcomes, it 
might have been expected that transplant outcomes would have been better in 
recipients of kidneys from donors with IRB (15, 19). The number of recipients of 
kidneys from donors with IRB in the present study may not have been sufficient to 
demonstrate the advantage of younger donor age on transplant outcome. 
 
The present study is the first to report in detail on different categories of IRB 
in a national cohort of deceased organ donors, and provides important information on 
which to base future transplant policy for managing the risk of disease transmission. 
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The numbers presented likely represent an underestimate of potential donors with IRB 
in the donor population, because of underreporting. This is evidenced by the small 
number of reported MSM in the registry (0.44%), whilst estimates from a recent US 
census analysis and meta-analysis estimated that around 3.9% of the US adult male 
populations are MSM, and in the UK it is estimated that 2.0-2.5% of the adult male 
population are MSM (20,21).  
 
Research suggests that a patient would be willing to accept a kidney from a 
donor with IRB if the organ was deemed otherwise healthy (22): individuals are more 
concerned about the perceived poor quality of the organ and the risk of disease 
transmission rather than having a prejudice or concern about a particular type of 
increased risk behavior per se (22). 
While the present study indicates that a history of IRB, particularly IVDU, in 
seronegative potential donors is associated with a reduction in organs being accepted 
for transplantation, such donors represent a valuable source of organs for 
transplantation and the risk of disease transmission in the context of UK blood borne 
virus epidemiology is relatively small. Moreover, recent advances in the management 
of transmissible viruses particularly HCV, means that even if viral disease 
transmission occurs it can in many cases be successfully managed (23). It has also 
been suggested that kidneys from seronegative donors with a history of IRB may be a 
valuable source of organs for potential recipients with an increased likelihood of 
death whilst on the waiting list (24-26).  When organs from donors with a history of 
IRB are used for transplantation it would be prudent for all centers to test recipients 
within an appropriate time period following transplantation in order to exclude donor 
derived infection. 
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Conclusions 
Around 4% of UK deceased donors have an identifiable history of behavior 
associated with an increased risk of blood borne transmissible viral infection, but are 
seronegative at time of donation. Three quarters of such donors provide organs for 
transplantation with good transplant outcomes, and apparently low risk of disease 
transmission. Recent advances in the treatment of viral disease, particularly HCV, 
further reduce the risks associated with disease transmission. Donors with a history of 
IRB provide a valuable source of organs for transplantation with good transplant 
outcomes and there is scope for increasing the use of organs from donors with IRB, in 
particular for donors with a history of IVDU. 
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Figure Legend 
 
Figure 1. Flow diagram for seronegative organ donors identified with increased risk 
behavior 
 
Figure 2. Proceeding and nonproceeding seronegative consented organ donors 
according to whether or not they had history increased risk behavior. 
IVDU=Intravenous drug use; IRB= Increased Risk Behavior 
* All p values refer to category of increased risk behavior compared to all donors with 
no history of increased risk behavior. 
 
Figure 3. Number of seronegative potential donors with increased risk behavior 
whose organs were used for transplantation and those whose were not used for 
transplantation.  
Proportion of potential organ donors with a history of high-risk behavior who did not 
proceed to organ donation is shown above each column.  
 
Figure 4a and Figure 4b. Patient and Graft survival of kidney transplant recipients 
from organ donors with a history of increased risk behavior and from all other 
deceased organ donors 
 
Figure 5a and Figure 5b. Patient and Graft survival of liver transplant recipients from 
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organ donors with increased risk behavior and all other deceased organ donors  
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 Potential donors with increased 
risk behavior (n=144) 
Potential donors with no 
increased risk behavior 
(n=141) 
p value 
Nonproceeding 
(n= 82) 
Proceeding 
(n= 62) 
Nonproceeding  
(n=99) 
Proceeding 
(n=42) 
 
Age (y) (median 
and IQR) 
45 (35-53) 36 (31-47) 52 (44-59) 47 (38-56) <0.001 
Male /Female 
(%) 
66 (80.5%)/ 16 
(19.5%) 
38 (62%)/ 24 
(38%) 
60 (60.6%)/ 39 
(39.4%) 
26  (61.3%)/ 
16 (38.7%) 
0.044 
White Ethnicity 
(%) 
79 (96.3%) 56 (91.8%) 89 (89.9%) 36 (85.7%) 0.128 
HIV antibody 3 (3.7%) 2 (3.2%) 8 (8.5%) 1 (2.4%) 0.420 
HCV antibody 77 (93.9%) 59 (95.1%) 62 (62.6%) 27 (64.2%) <0.001 
HBsAg positive 3 (3.7%) 3 (4.8%) 13 (14.3%) 12 (28.6%) <0.001 
HTLV 1 (0.7%) 0 19 (17%) 2 (4%) <0.001 
Increased risk 
behavior – All 
82 62    
High risk sexual 
behavior 
5 (6.1%) 2 (3.2%)    
IVDU 61 (74.3%) 52 (83.9%)    
Prison 16 (19.5%) 8 (12.9%)    
Organs 
Transplanted 
    <0.001 
Liver  48  25  
Kidney  11  32  
Other organs  0  0  
Table 1. Clinical characteristics of potential and proceeding organ donors that 
were seropositive for Human Immunodeficiency Virus (HIV), Hepatitis C Virus 
(HCV), HBsAg (Hepatitis B Surface Antigen) and Human T Lymphotropic 
Virus (HTLV) 
IVDU=Intravenous Drug User/Use 
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 Potential Donors with 
increased risk 
behaviors 
(n= 515) 
Potential donors with 
no increased risk 
behaviors 
(n= 16462) 
p value 
Age (y) (median, 
IQR) 
40 (32-50) 53 (40-64) <0.001 
Male/Female (%) 448 (87%)/ 67 (13%) 8942 (54%)/7513 
(46%) 
<0.001 
White ethnicity 
(%) 
467 (91%) 15 482 (94%) 0.002 
DBD/DCD (%) 271 (53%)/ 244 (47%) 8976 (55%)/ 7486 
(45%) 
0.393 
Past History of 
Alcohol Abuse 
  <0.001 
Yes 241 (47%) 2301 (14%)  
No 256 (50%) 12 926 (79%)  
Unknown/Not stated 18 (3%) 1235 (8%)  
Past History of 
Hypertension 
  <0.001 
Yes 81 (16%0 4587 (28%)  
No 418 (81%) 10 525 (64%)  
Unknown/Unstated 16 (3%) 1350 (8%)  
Past History of 
Cardiac Disease 
  <0.001 
Yes 44 (9%) 2003 (12%)  
No 447 (87%) 13 065 (79%)  
Unknown/Unstated 24 (5%) 1394 (8%)  
Past History of 
Diabetes 
  0.009 
Yes 35 (7%) 1284 (8%)  
No 460 (89%) 14 003 (85%)  
Unknown/ Unstated 20 (4%) 1175 (7%)  
Smoking History   <0.001 
Yes 408 (79%) 6655 (40%)  
No 94 (18%) 8649 (53%)  
Unknown/Unstated 13 (3%) 1158 (7%)  
Table 2. Clinical Characteristics of seronegative potential donors with increased 
risk behavior compared with all other deceased organ donors 
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 Odds Ratio (95% Confidence 
Intervals) 
p value 
Donor age (y) 1.035 (1.033 -1.038) <0.001 
Past medical history 
of hypertension vs. no 
past medical history 
of hypertension 
1.192 (1.094-1.29) <0.001 
High risk sexual 
behavior vs. no high 
risk sexual behavior 
1.373 (0.900-2.094) 0.141 
Imprisonment vs. no 
history of 
Imprisonment 
0.859 (0.570-1.295) 0.468 
Historical IVDU vs. 
no history of IVDU 
1.984 (1.205-3.268) 0.007 
Recent IVDU vs. no 
history of IVDU 
3.551 (2.373-5.315) <0.001 
Table 3. The likelihood of potential donors not proceeding to become actual 
organ donors based on the presence of selected risk factors. 
IVDU=Intravenous Drug User/Use 
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 Proceeding donors with 
a history of increased 
risk behavior (n= 392) 
All other deceased 
proceeding organ 
donors 
(n= 12 345) 
p value 
Age (y) (median, 
IQR) 
39 (30-48) 50 (38-61) <0.001 
Gender   <0.001 
Male/Female  341 (87.0%)/ 51 (13.0%) 6492(52.6%)/ 5849 
(47.4%) 
 
Not stated 0 4 (<0.5%)  
DBD/DCD (%) 250(63.8%)/ 142(36.2%) 8476 (68.3%)/ 
3918(31.7%) 
0.056 
Ethnicity    0.004 
White 352 (89.8%) 11 540 (93.5%)  
Nonwhite 40 (10.2%) 805 (6.5%)  
Body Mass Index 
(BMI) 
24.4 (22.0-27.5) 25.7 (22.9-29.0) <0.001 
Past History 
Alcohol Abuse 
  <0.001 
Yes 165 (42.1%) 1611 (13.1%)  
No 218 (55.6%) 10 294 (83.4%)  
Unknown/Not 
stated 
9 (2.3%) 440 (3.6%)  
Smoking History   <0.001 
Yes 311 (79.3%) 5327 (43.2%)  
No 77 (19.6%) 6651 (53.9%)  
Unknown/Unstated 4 (1.0%) 367 (3.0%)  
Past History of 
Cardiac disease 
  0.176 
Yes 32 (8.2%) 1267 (10.3%)  
No 348 (88.8%) 10 549 (85.5%)  
Unknown/Unstated 12 (3.1%) 529 (4.3%)  
Past History of 
Hypertension 
  <0.001 
Yes 61 (15.6%) 3244 (26.3%)  
No 325 (82.9%) 8603 (69.7%)  
Unknown/Unstated 6 (1.5%) 498 (4%)  
Past History of 
Diabetes 
  0.568 
Yes 22 (5.6%) 822 (6.7%)  
No 360 (91.8%) 11 138 (90.2%)  
Unknown/Unstated 10 (2.6%) 385 (3.1%)  
 
Table 4. Clinical Characteristics of deceased seronegative proceeding organ 
donors with increased risk behavior compared with all other deceased organ 
donors. 
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 Increased Risk 
Behavior Donors  
(n= 624) 
All other deceased 
donors 
(n= 18 881) 
p value 
Age (y) 48 (38-56) 50 (39-60) <0.001 
Gender    
Male/Female (%) 393 (63.1%)/ 230 
(36.9%) 
11 788 (62.5%)/ 
7083(37.5%) 
0.552 
Not stated 1 (<0.5%) 38 (<0.5%)  
Ethnicity    
White/Nonwhite 
(%) 
460 (73.8%)/ 163 
(26.2%) 
14663 (77.7%)/ 4208 
(22.3%) 
0.009 
Not stated 1 (<0.5%) 38 (<0.5%)  
*cRF >85% 63 (10.0%) 1800 (9.5%) 0.889 
HLA Group   0.256 
1 74 (11.9%) 2719 (14.4%)  
2 215 (34.5%) 6654 (35.3%)  
3 288 (46.2%) 8198 (43.4%)  
4 46 (7.4%) 1310 (7.0%)  
Missing/Not stated 1 (<0.5%) 29 (<0.5%)  
Primary Renal 
Disease 
  0.522 
Diabetic 
Nephropathy 
43 (6.9%) 1544 (7.6%)  
Glomerulonephritis 110 (17.6%) 3347 (17.7%)  
Pyelonephritis 50 (8.1%) 1437 (5.3%)  
Polycystic Kidney 
Disease 
70 (11.2%) 2261 (12.0%)  
Other/ Not stated 351 (56.3%) 10 292 (57.4%)  
Time on dialysis 
(days) 
1295 (727-1994) 1252 (706-1955) 0.552 
Waiting time 
(days) 
827 (361-1370) 832 (354-1450) 0.489 
 
Table 5. Clinical characteristics of recipients of seronegative deceased donor 
kidneys according to whether or not the donor had a history of increased risk 
behavior.  
*cRF (calculated reaction frequency) = HLA antibody reaction frequency. 
Data shown as median and IQR 
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 Increased risk 
behavior Donors 
(n= 278) 
All other 
deceased donors 
(n= 8756) 
p value 
Age (y) 53 (43-59) 51 (37-59) 0.111 
Gender   0.012 
Male/Female (%) 190 (68.4%)/ 88 
(31.6%) 
5205 (59.5%)/ 
3546 (40.5%) 
 
Unknown/ Unstated 0 5(<0.5%)  
Ethnicity   0.148 
White (%) 244 (87.8%) 7404 (84.6%)  
Nonwhite (%) 34 (12.2%) 1348 (15.4%)  
Unknown/Unstated  4 (<0.5%)  
Urgent Status 42 (15.1%) 1483 (16.9%) 0.421 
UK End Stage 
Liver Disease score 
53 (50-58) 55 (51-59) 0.016 
50-54    
>55    
Missing/Not stated    
Recipient HCV 
antibody positive 
12 (4.3%) 484 (5.5%) <0.001 
Primary Liver 
Disease 
  0.012 
HCV cirrhosis 38 (13.7%) 950 (10.7%)  
Alcoholic Liver 
Disease 
67 (24%) 1561 (17.7%)  
Other/Not stated 173 (62.2%) 6245 (71.3%)  
 
Table 6. Clinical characteristics of recipients of seronegative deceased donor 
livers according to whether or not the donor had a history of increased risk 
behavior  
HCV= Hepatitis C Virus 
Data shown as Median and IQR 
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 Hazard Ratio p value 
Donor Age (y) 1.009 (1.005-1.012) <0.001 
Recipient Age (y) 1.056 <0.001 
Donor Type   
DCD 1.00 - 
DBD 1.151 (1.042-1.272) 0.006 
Cold Ischemic Time 1.009 (1.002-1.016) 0.012 
HLA Mismatch   
1 0.840 (0.696-0.999) 0.0599 
2 0.857 (0.729-1.001) 0.0573 
3 0.883 (0.757-1.019) 0.1052 
4 1.00 - 
Recipient Sex   
Female 1.00 - 
Male 1.101 (1.010-1.200) 0.028 
Primary renal disease   
All other causes 1.00 - 
Glomerulonephritis 0.823 (0.731-0.927) <0.001 
Diabetic Nephropathy 1.595 (1.409-1.805) <0.001 
Pyelonephritis 1.041 (0.896-1.221) 0.609 
Polycystic kidney 
disease 
0.661 (0.578-0.763) <0.001 
History of 
Hypertension 
  
No history of 
hypertension 
1.00 - 
Hypertension 1.186 (1.079-1.305) <0.001 
Unknown history of 
hypertension 
1.243 (1.037-1.491) 0.02 
Increased Risk 
Behavior 
  
No history of Increased 
risk behavior 
1.00 - 
Increased risk behavior 1.102 (0.833-1.457) 0.498 
Subtypes of Increased 
Risk Behavior 
  
Recent IVDU 0.482 (0.136-1.713) 0.230 
Historical IVDU 0.763 (0.326-1.787) 0.534 
Imprisonment 0.804 (0.514-1.256) 0.338 
High risk sexual 
behavior 
1.897 (1.253-2.872) 0.003 
Subtypes of high risk 
sexual behavior 
  
High risk partner 3.004 (1.592-5.667) <0.001 
Men who have sex with 
men 
1.376 (0.770-2.461) 0.281 
Not specified  3.819 (0.944-15.450) 0.060 
Prior high risk partner 2.510 (0.351-17.930) 0.359 
 
Supplementary Table 1. Cox proportional hazards regression model for patient 
survival following renal transplantation 
*IVDU=Intravenous drug use/user 
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